Nimbolide

Key Product Details

Product Description

Nimbolide inhibits auto-ubiquitination of the E3 ligase RNF114 and p21 ubiquitination in vitro. This compound impairs proliferation of triple-negative breast cancer cell lines. Nimbolide also induces apoptotic cell death in a Waldenströms macroglobulinemia cell line (BCWM1) and inhibits tumor growth in a xenograft model of Waldenströms macroglobulinemia.

Nimbolide can be used for the development of Degraders that utilize RNF114 as an E3 ligase for Targeted Protein Degradation.

Product Specifications for Nimbolide

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Nimbolide

The following data is based on the product molecular weight 466.53.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.14 mL	10.72 mL	21.43 mL
5 mM	0.43 mL	2.14 mL	4.29 mL
10 mM	0.21 mL	1.07 mL	2.14 mL
50 mM	0.04 mL	0.21 mL	0.43 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Spradin Harnessing the anti-cancer natural product nimbolide for targeted protein degradation. Nat.Chem.Biol. 2019 PMID: 31209351
• Tong A nimbolide-based kinase degrader preferentially degrades oncogenic BCR-ABL. ACS Chem.Biol. 2020 PMID: 32568522
• Chitta Nimbolide targets BCL2 and induces apoptosis in preclinical models of Waldenströms macroglobulinemia. Blood Cancer J. 2014 PMID: 25382610

Product Documents for Nimbolide